Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Biotech Services HoldingsHKSE:08037 -3.08%19 3-Year ROIIC % is 5,638.75 as of Dec. 2025, which is 9955% above its 10-year median of 56.08. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.26 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, China Biotech Services Holdings ranks better than 98.03% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
China Biotech Services Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 5,638.75%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
HKSE:08037's 3-Year ROIIC % is ranked better than 98.03% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.03
vs HKSE:08037: 5638.75
China Biotech Services Holdings (HKSE:08037) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
China Biotech Services Holdings 3-Year ROIIC % Related Terms
China Biotech Services Holdings 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings 3-Year ROIIC % Chart
HKSE:08037 vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, China Biotech Services Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
China Biotech Services Holdings (HKSE:08037) has a 3-Year ROIIC % of 5,638.75 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Biotech Services Holdings and its competitors. This is 9955% above median its historical median of 56.08. According to the industry distribution chart, China Biotech Services Holdings ranks #4 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 2%.
Is China Biotech Services Holdings' 3-Year ROIIC % too high?
China Biotech Services Holdings' current 3-Year ROIIC % of 5,638.75 is 9955% above median its 10-year median of 56.08. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.03. China Biotech Services Holdings' value of 5,638.75 is 18795733.3% above this industry median. Based on the distribution chart, China Biotech Services Holdings ranks #4 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #4 out of 203 companies for 3-Year ROIIC %. This places China Biotech Services Holdings in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.03. China Biotech Services Holdings' value of 5,638.75 is 18795733.3% above this benchmark. While the company's 10-year median is 56.08 vs. the industry median of 0.03, China Biotech Services Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.03, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Biotech Services Holdings's current 3-Year ROIIC % of 5,638.75 is 18795733.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current 3-Year ROIIC % is 5,638.75, which is 9955% above median its own 10-year median of 56.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.26, compared to a current price of HK$0.63 — trading 142.3% above its estimated fair value. The current 3-Year ROIIC % is 5,638.75, which is 9955% above median its 10-year median of 56.08 and 18795733.3% above the Medical Diagnostics & Research industry median of 0.03. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current 3-Year ROIIC % is 5,638.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.63 is trading 142.3% above its estimated GF Value™ of HK$0.26.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
3-Year ROIIC %: 5,638.75 (9955% above median its 10-year median of 56.08)
GF Value™: HK$0.26 vs. price of HK$0.63 (142.3% above fair value)
Industry Position: 18795733.3% above the Medical Diagnostics & Research median (#4 of 203)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score
Get the complete analysis for HKSE:08037
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
